Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Novogen Limited (KZIA : NSDQ)

• Company Description    Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Kazia Therapeutics Limited, formerly known as Novogen Limited, is based in Sydney, Australia. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $5.23 Daily Weekly Monthly 20 Day Moving Average: 22,627 shares Shares Outstanding: 13.20 (millions) Market Capitalization: $69.04 (millions) Beta: 2.39 52 Week High: $12.28 52 Week Low: $5.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -30.73% -24.10% 12 Week -28.02% -21.90% Year To Date -37.89% -26.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Three International Towers Level 24 300 Barangaroo Avenue - Sydney,C3 2000 AUS ph: 61-2-9472-4101 fax: 61-2-9476-0388 investment.consultant@novogen.com http://www.kaziatherapeutics.com

• General Corporate Information    Officers James Garner - Chief Executive Officer Iain Ross - Chairman Kate Hill - Company Secretary Bryce Carmine - Director Steven Coffey - Director Peer Information Novogen Limited (CORR.) Novogen Limited (RSPI) Novogen Limited (CGXP) Novogen Limited (BGEN) Novogen Limited (GTBP) Novogen Limited (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 48669G105 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 13.20 Most Recent Split Date: 7.00 (0.25:1) Beta: 2.39 Market Capitalization: $69.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.27 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.72 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - - 12/31/21 - 2.20 09/30/21 - - Quick Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - - Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - 1.41 09/30/21 - - Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©